Recent insights into farnesoid X receptor in non-alcoholic fatty liver disease

World Journal of Gastroenterology

Volumn 20, Issue 37, 2014, Pages 13493-13500

  Xu, Jiao Ya ^a   Li, Zhong Ping ^a   Zhang, Li ^a   Ji, Guang ^a  

^a SHANGHAI UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

Author keywords

Farnesoid X receptor; Lipid metabolism; Mechanism; Non alcoholic fatty liver disease; Therapy

Indexed keywords

3 [2 [2 CHLORO 4 [3 (2,6 DICHLOROPHENYL) 5 ISOPROPYL 4 ISOXAZOLYLMETHOXY]PHENYL]VINYL]BENZOIC ACID; FARNESOID X RECEPTOR; FATTY ACID; HORMONE RECEPTOR STIMULATING AGENT; INT 767; OBETICHOLIC ACID; TRIACYLGLYCEROL; TUROFEXORATE ISOPROPYL; UNCLASSIFIED DRUG; ANTIINFLAMMATORY AGENT; ANTILIPEMIC AGENT; AUTACOID; BILE ACID; CELL RECEPTOR; FARNESOID X-ACTIVATED RECEPTOR;

BILE ACID METABOLISM; CHOLESTEROL METABOLISM; FATTY ACID METABOLISM; HEPATITIS; HOMEOSTASIS; HUMAN; LIPID METABOLISM; NONALCOHOLIC FATTY LIVER; PATHOGENESIS; PROTEIN FUNCTION; REVIEW; AGONISTS; ANIMAL; CARBOHYDRATE METABOLISM; COMPLICATION; DISEASE COURSE; DRUG EFFECTS; LIVER; LIVER CIRRHOSIS; METABOLISM; NON-ALCOHOLIC FATTY LIVER DISEASE; SIGNAL TRANSDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; BILE ACIDS AND SALTS; CARBOHYDRATE METABOLISM; DISEASE PROGRESSION; HEPATITIS; HUMANS; HYPOLIPIDEMIC AGENTS; INFLAMMATION MEDIATORS; LIPID METABOLISM; LIVER; LIVER CIRRHOSIS; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, CYTOPLASMIC AND NUCLEAR; SIGNAL TRANSDUCTION;

EID: 84910005718     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i37.13493     Document Type: Review

References (86)

1. Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease - the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther 2014; 39: 254-269 [PMID: 24308774 DOI: 10.1111/apt.12569]
2. Sanyal AJ. NASH: A global health problem. Hepatol Res 2011; 41: 670-674 [PMID: 21711426 DOI: 10.1111/j.1872-034X.2011.00824.x]
3. Wong RJ, Cheung R, Ahmed A. Nonalcoholic steatohepatitis is the most rapidly growing indication for liver transplantation in patients with hepatocellular carcinoma in the U.S. Hepatology 2014; 59: 2188-2195 [PMID: 24375711 DOI: 10.1002/hep.26986]
4. Lin XF, Shi KQ, You J, Liu WY, Luo YW, Wu FL, Chen YP, Wong DK, Yuen MF, Zheng MH. Increased risk of colorectal malignant neoplasm in patients with nonalcoholic fatty liver disease: a large study. Mol Biol Rep 2014; 41: 2989-2997 [PMID: 24449368 DOI: 10.1007/s11033-014-3157-y]
5. El Azeem HA, Khalek el-SA, El-Akabawy H, Naeim H, Khalik HA, Alfifi AA. Association between nonalcoholic fatty liver disease and the incidence of cardiovascular and renal events. J Saudi Heart Assoc 2013; 25: 239-246 [PMID: 24198448 DOI: 10.1016/j.jsha.2013.07.004]
6. Targher G, Chonchol M, Zoppini G, Abaterusso C, Bonora E. Risk of chronic kidney disease in patients with nonalcoholic fatty liver disease: is there a link? J Hepatol 2011; 54: 1020-1029 [PMID: 21145850 DOI: 10.1016/j.jhep.2010.11.007]
7. Bhatia LS, Curzen NP, Calder PC, Byrne CD. Non-alcoholic fatty liver disease: a new and important cardiovascular risk factor? Eur Heart J 2012; 33: 1190-1200 [PMID: 22408036 DOI: 10.1093/eurheartj/ehr453]
8. Bonapace S, Valbusa F, Bertolini L, Pichiri I, Mantovani A, Rossi A, Zenari L, Barbieri E, Targher G. Nonalcoholic fatty liver disease is associated with aortic valve sclerosis in patients with type 2 diabetes mellitus. PLoS One 2014; 9: e88371 [PMID: 24505484 DOI: 10.1371/journal.pone.0088371]
9. Lefebvre P, Cariou B, Lien F, Kuipers F, Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev 2009; 89: 147-191 [PMID: 19126757 DOI: 10.1152/physrev.00010.2008]
10. Thomas C, Pellicciari R, Pruzanski M, Auwerx J, Schoonjans K. Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 2008; 7: 678-693 [PMID: 18670431 DOI: 10.1038/nrd2619]
11. Parks DJ, Blanchard SG, Bledsoe RK, Chandra G, Consler TG, Kliewer SA, Stimmel JB, Willson TM, Zavacki AM, Moore DD, Lehmann JM. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999; 284: 1365-1368 [PMID: 10334993]
12. Wang YD, Chen WD, Moore DD, Huang W. FXR: a metabolic regulator and cell protector. Cell Res 2008; 18: 1087-1095 [PMID: 18825165 DOI: 10.1038/cr.2008.289]
13. Laffitte BA, Kast HR, Nguyen CM, Zavacki AM, Moore DD, Edwards PA. Identification of the DNA binding specificity and potential target genes for the farnesoid X-activated receptor. J Biol Chem 2000; 275: 10638-10647 [PMID: 10744760]
14. Yang ZX, Shen W, Sun H. Effects of nuclear receptor FXR on the regulation of liver lipid metabolism in patients with non-alcoholic fatty liver disease. Hepatol Int 2010; 4: 741-748 [PMID: 21286345 DOI: 10.1007/s12072-010-9202-6]
15. Bjursell M, Wedin M, Admyre T, Hermansson M, Böttcher G, Göransson M, Lindén D, Bamberg K, Oscarsson J, Bohlooly-Y M. Ageing Fxr deficient mice develop increased energy expenditure, improved glucose control and liver damage resembling NASH. PLoS One 2013; 8: e64721 [PMID: 23700488]
16. Kong B, Luyendyk JP, Tawfik O, Guo GL. Farnesoid X receptor deficiency induces nonalcoholic steatohepatitis in low-density lipoprotein receptor-knockout mice fed a high-fat diet. J Pharmacol Exp Ther 2009; 328: 116-122 [PMID: 18948497 DOI: 10.1124/jpet.108.144600]
17. Ma K, Saha PK, Chan L, Moore DD. Farnesoid X receptor is essential for normal glucose homeostasis. J Clin Invest 2006; 116: 1102-1109 [PMID: 16557297 DOI: 10.1172/JCI25604]
18. Watanabe M, Houten SM, Wang L, Moschetta A, Mangelsdorf DJ, Heyman RA, Moore DD, Auwerx J. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest 2004; 113: 1408-1418 [PMID: 15146238 DOI: 10.1172/JCI21025]
19. Cipriani S, Mencarelli A, Palladino G, Fiorucci S. FXR activation reverses insulin resistance and lipid abnormalities and protects against liver steatosis in Zucker (fa/fa) obese rats. J Lipid Res 2010; 51: 771-784 [PMID: 19783811 DOI: 10.1194/Jlr.M001602]
20. Zhang S, Wang J, Liu Q, Harnish DC. Farnesoid X receptor agonist WAY-362450 attenuates liver inflammation and fibrosis in murine model of non-alcoholic steatohepatitis. J Hepatol 2009; 51: 380-388 [PMID: 19501927 DOI: 10.1016/j.jhep.2009.03.025]
21. Day CP, James OF. Steatohepatitis: a tale of two "hits"? Gastroenterology 1998; 114: 842-845 [PMID: 9547102]
22. Nomura K, Yamanouchi T. The role of fructose-enriched diets in mechanisms of nonalcoholic fatty liver disease. J Nutr Biochem 2012; 23: 203-208 [PMID: 22129639 DOI: 10.1016/j.jnutbio.2011.09.006]
23. Mantena SK, King AL, Andringa KK, Eccleston HB, Bailey SM. Mitochondrial dysfunction and oxidative stress in the pathogenesis of alcohol- and obesity-induced fatty liver diseases. Free Radic Biol Med 2008; 44: 1259-1272 [PMID: 18242193 DOI: 10.1016/j.freeradbiomed.2007.12.029]
24. Lanktree MB, Johansen CT, Joy TR, Hegele RA. A translational view of the genetics of lipodystrophy and ectopic fat deposition. Prog Mol Biol Transl Sci 2010; 94: 159-196 [PMID: 21036325 DOI: 10.1016/S1877-1173(10)94006-4]
25. Li Y, Jadhav K, Zhang Y. Bile acid receptors in non-alcoholic fatty liver disease. Biochem Pharmacol 2013; 86: 1517-1524 [PMID: 23988487 DOI: 10.1016/j.bcp.2013.08.015]
26. Rizzo G, Renga B, Mencarelli A, Pellicciari R, Fiorucci S. Role of FXR in regulating bile acid homeostasis and relevance for human diseases. Curr Drug Targets Immune Endocr Metabol Disord 2005; 5: 289-303 [PMID: 16178789]
27. Li T, Chiang JY. Bile Acid signaling in liver metabolism and diseases. J Lipids 2012; 2012: 754067 [PMID: 21991404 DOI: 10.1155/2012/754067]
28. Allen K, Jaeschke H, Copple BL. Bile acids induce inflammatory genes in hepatocytes: a novel mechanism of inflammation during obstructive cholestasis. Am J Pathol 2011; 178: 175-186 [PMID: 21224055 DOI: 10.1016/j.ajpath.2010.11.026]
29. Hofmann AF. The continuing importance of bile acids in liver and intestinal disease. Arch Intern Med 1999; 159: 2647-2658 [PMID: 10597755]
30. Chiang JY. Bile acid metabolism and signaling. Compr Physiol 2013; 3: 1191-1212 [PMID: 23897684 DOI: 10.1002/cphy.c120023]
31. Goodwin B, Jones SA, Price RR, Watson MA, McKee DD, Moore LB, Galardi C, Wilson JG, Lewis MC, Roth ME, Maloney PR, Willson TM, Kliewer SA. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol Cell 2000; 6: 517-526 [PMID: 11030332 DOI: 10.1016/S1097-2765(00)00051-4]
32. Chiang JY. Bile acid regulation of gene expression: roles of nuclear hormone receptors. Endocr Rev 2002; 23: 443-463 [PMID: 12202460 DOI: 10.1210/er.2000-0035]
33. Chen Q, Jiang Y, An Y, Zhao N, Zhao Y, Yu C. Soluble FGFR4 extracellular domain inhibits FGF19-induced activation of FGFR4 signaling and prevents nonalcoholic fatty liver disease. Biochem Biophys Res Commun 2011; 409: 651-656 [PMID: 21616061 DOI: 10.1016/j.bbrc.2011.05.059]
34. Inagaki T, Choi M, Moschetta A, Peng L, Cummins CL, McDonald JG, Luo G, Jones SA, Goodwin B, Richardson JA, Gerard RD, Repa JJ, Mangelsdorf DJ, Kliewer SA. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab 2005; 2: 217-225 [PMID: 16213224 DOI: 10.1016/j.cmet.2005.09.001]
35. Song KH, Li T, Owsley E, Strom S, Chiang JY. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009; 49: 297-305 [PMID: 19085950 DOI: 10.1002/hep.22627]
36. Eloranta JJ, Kullak-Ublick GA. The role of FXR in disorders of bile acid homeostasis. Physiology (Bethesda) 2008; 23: 286-295 [PMID: 18927204 DOI: 10.1152/physiol.00020.2008]
37. Geier A, Wagner M, Dietrich CG, Trauner M. Principles of hepatic organic anion transporter regulation during cholestasis, inflammation and liver regeneration. Biochim Biophys Acta 2007; 1773: 283-308 [PMID: 17291602 DOI: 10.1016/j.bbamcr.2006.04.014]
38. Pollheimer MJ, Fickert P, Stieger B. Chronic cholestatic liver diseases: clues from histopathology for pathogenesis. Mol Aspects Med 2014; 37: 35-56 [PMID: 24141039 DOI: 10.1016/j.mam.2013.10.001]
39. Kast HR, Goodwin B, Tarr PT, Jones SA, Anisfeld AM, Stoltz CM, Tontonoz P, Kliewer S, Willson TM, Edwards PA. Regulation of multidrug resistance-associated protein 2 (ABCC2) by the nuclear receptors pregnane X receptor, farnesoid X-activated receptor, and constitutive androstane receptor. J Biol Chem 2002; 277: 2908-2915 [PMID: 11706036 DOI: 10.1074/jbc.M109326200]
40. Boyer JL, Trauner M, Mennone A, Soroka CJ, Cai SY, Moustafa T, Zollner G, Lee JY, Ballatori N. Upregulation of a basolateral FXR-dependent bile acid efflux transporter OSTalpha-OSTbeta in cholestasis in humans and rodents. Am J Physiol Gastrointest Liver Physiol 2006; 290: G1124-G1130 [PMID: 16423920 DOI: 10.1152/ajpgi.00539.2005]
41. Musso G, Gambino R, Cassader M. Cholesterol metabolism and the pathogenesis of non-alcoholic steatohepatitis. Prog Lipid Res 2013; 52: 175-191 [PMID: 23206728 DOI: 10.1016/j.plipres.2012.11.002]
42. Enjoji M, Yasutake K, Kohjima M, Nakamuta M. Nutrition and nonalcoholic Fatty liver disease: the significance of cholesterol. Int J Hepatol 2012; 2012: 925807 [PMID: 22550592 DOI: 10.1155/2012/925807]
43. Sinal CJ, Tohkin M, Miyata M, Ward JM, Lambert G, Gonzalez FJ. Targeted disruption of the nuclear receptor FXR/BAR impairs bile acid and lipid homeostasis. Cell 2000; 102: 731-744 [PMID: 11030617]
44. Lambert G, Amar MJ, Guo G, Brewer HB, Gonzalez FJ, Sinal CJ. The farnesoid X-receptor is an essential regulator of cholesterol homeostasis. J Biol Chem 2003; 278: 2563-2570 [PMID: 12421815 DOI: 10.1074/jbc.M209525200]
45. Van Rooyen DM, Larter CZ, Haigh WG, Yeh MM, Ioannou G, Kuver R, Lee SP, Teoh NC, Farrell GC. Hepatic free cholesterol accumulates in obese, diabetic mice and causes nonalcoholic steatohepatitis. Gastroenterology 2011; 141: 1393-1403, 1403.e1-5 [PMID: 21703998 DOI: 10.1053/j.gastro.2011.06.040]
46. Langhi C, Le May C, Kourimate S, Caron S, Staels B, Krempf M, Costet P, Cariou B. Activation of the farnesoid X receptor represses PCSK9 expression in human hepatocytes. FEBS Lett 2008; 582: 949-955 [PMID: 18298956 DOI: 10.1016/j.febslet.2008.02.038]
47. Li G, Thomas AM, Williams JA, Kong B, Liu J, Inaba Y, Xie W, Guo GL. Farnesoid X receptor induces murine scavenger receptor Class B type I via intron binding. PLoS One 2012; 7: e35895 [PMID: 22540009 DOI: 10.1371/journal.pone.0035895]
48. Malerød L, Sporstøl M, Juvet LK, Mousavi SA, Gjøen T, Berg T, Roos N, Eskild W. Bile acids reduce SR-BI expression in hepatocytes by a pathway involving FXR/RXR, SHP, and LRH-1. Biochem Biophys Res Commun 2005; 336: 1096-1105 [PMID: 16168958 DOI: 10.1016/j.bbrc.2005.08.237]
49. Ma Y, Huang Y, Yan L, Gao M, Liu D. Synthetic FXR agonist GW4064 prevents diet-induced hepatic steatosis and insulin resistance. Pharm Res 2013; 30: 1447-1457 [PMID: 23371517 DOI: 10.1007/s11095-013-0986-7]
50. Li T, Matozel M, Boehme S, Kong B, Nilsson LM, Guo G, Ellis E, Chiang JY. Overexpression of cholesterol 7α-hydroxylase promotes hepatic bile acid synthesis and secretion and maintains cholesterol homeostasis. Hepatology 2011; 53: 996-1006 [PMID: 21319191 DOI: 10.1002/hep.24107]
51. Jiang ZG, Robson SC, Yao Z. Lipoprotein metabolism in nonalcoholic fatty liver disease. J Biomed Res 2013; 27: 1-13 [PMID: 23554788 DOI: 10.7555/JBR.27.20120077]
52. Horton JD, Goldstein JL, Brown MS. SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 2002; 109: 1125-1131 [PMID: 11994399 DOI: 10.1172/JCI15593]
53. Xiong X, Wang X, Lu Y, Wang E, Zhang Z, Yang J, Zhang H, Li X. Hepatic steatosis exacerbated by endoplasmic reticulum stress-mediated downregulation of FXR in aging mice. J Hepatol 2014; 60: 847-854 [PMID: 24333182 DOI: 10.1016/j.jhep.2013.12.003]
54. Li X, Li Y, Yang W, Xiao C, Fu S, Deng Q, Ding H, Wang Z, Liu G, Li X. SREBP-1c overexpression induces triglycerides accumulation through increasing lipid synthesis and decreasing lipid oxidation and VLDL assembly in bovine hepatocytes. J Steroid Biochem Mol Biol 2014; 143: 174-182 [PMID: 24565561 DOI: 10.1016/j.jsbmb.2014.02.009]
55. Trauner M, Claudel T, Fickert P, Moustafa T, Wagner M. Bile acids as regulators of hepatic lipid and glucose metabolism. Dig Dis 2010; 28: 220-224 [PMID: 20460915 DOI: 10.1159/000282091]
56. Fuchs M. Non-alcoholic Fatty liver disease: the bile Acid-activated farnesoid x receptor as an emerging treatment target. J Lipids 2012; 2012: 934396 [PMID: 22187656 DOI: 10.1155/2012/934396]
57. Pineda Torra I, Claudel T, Duval C, Kosykh V, Fruchart JC, Staels B. Bile acids induce the expression of the human peroxisome proliferator-activated receptor alpha gene via activation of the farnesoid X receptor. Mol Endocrinol 2003; 17: 259-272 [PMID: 12554753 DOI: 10.1210/me.2002-0120]
58. Cyphert HA, Ge X, Kohan AB, Salati LM, Zhang Y, Hillgartner FB. Activation of the farnesoid X receptor induces hepatic expression and secretion of fibroblast growth factor 21. J Biol Chem 2012; 287: 25123-25138 [PMID: 22661717 DOI: 10.1074/jbc.M112.375907]
59. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, Chen JL, Jung DY, Zhang Z, Ko HJ, Kim JK, Véniant MM. Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 2009; 58: 250-259 [PMID: 18840786 DOI: 10.2337/db08-0392]
60. Seo JA, Kim NH. Fibroblast growth factor 21: a novel metabolic regulator. Diabetes Metab J 2012; 36: 26-28 [PMID: 22363918 DOI: 10.4093/dmj.2012.36.1.26]
61. Ge X, Yin L, Ma H, Li T, Chiang JY, Zhang Y. Aldo-keto reductase 1B7 is a target gene of FXR and regulates lipid and glucose homeostasis. J Lipid Res 2011; 52: 1561-1568 [PMID: 21642744 DOI: 10.1194/jlr.M015859]
62. Xu J, Li Y, Chen WD, Xu Y, Yin L, Ge X, Jadhav K, Adorini L, Zhang Y. Hepatic carboxylesterase 1 is essential for both normal and farnesoid X receptor-controlled lipid homeostasis. Hepatology 2014; 59: 1761-1771 [PMID: 24038130 DOI: 10.1002/hep.26714]
63. Lu Y, Ma Z, Zhang Z, Xiong X, Wang X, Zhang H, Shi G, Xia X, Ning G, Li X. Yin Yang 1 promotes hepatic steatosis through repression of farnesoid X receptor in obese mice. Gut 2014; 63: 170-178 [PMID: 23348961 DOI: 10.1136/gutjnl-2012-303150]
64. Wang YD, Chen WD, Wang M, Yu D, Forman BM, Huang W. Farnesoid X receptor antagonizes nuclear factor kappaB in hepatic inflammatory response. Hepatology 2008; 48: 1632-1643 [PMID: 18972444 DOI: 10.1002/hep.22519]
65. Inagaki T, Moschetta A, Lee YK, Peng L, Zhao G, Downes M, Yu RT, Shelton JM, Richardson JA, Repa JJ, Mangelsdorf DJ, Kliewer SA. Regulation of antibacterial defense in the small intestine by the nuclear bile acid receptor. Proc Natl Acad Sci USA 2006; 103: 3920-3925 [PMID: 16473946 DOI: 10.1073/pnas.0509592103]
66. Xu Z, Huang G, Gong W, Zhou P, Zhao Y, Zhang Y, Zeng Y, Gao M, Pan Z, He F. FXR ligands protect against hepatocellular inflammation via SOCS3 induction. Cell Signal 2012; 24: 1658-1664 [PMID: 22560881 DOI: 10.1016/j.cellsig.2012.04.015]
67. Peng X, Wu W, Zhu B, Sun Z, Ji L, Ruan Y, Zhou M, Zhou L, Gu J. Activation of farnesoid X receptor induces RECK expression in mouse liver. Biochem Biophys Res Commun 2014; 443: 211-216 [PMID: 24291500 DOI: 10.1016/j.bbrc.2013.11.082]
68. Jia X, Naito H, Yetti H, Tamada H, Kitamori K, Hayashi Y, Wang D, Yanagiba Y, Wang J, Ikeda K, Yamori Y, Nakajima T. Dysregulated bile acid synthesis, metabolism and excretion in a high fat-cholesterol diet-induced fibrotic steatohepatitis in rats. Dig Dis Sci 2013; 58: 2212-2222 [PMID: 23824403 DOI: 10.1007/s10620-013-2747-1]
69. Li J, Zhang Y, Kuruba R, Gao X, Gandhi CR, Xie W, Li S. Roles of microRNA-29a in the antifibrotic effect of farnesoid X receptor in hepatic stellate cells. Mol Pharmacol 2011; 80: 191-200 [PMID: 21511916 DOI: 10.1124/mol.110.068247]
70. Lee CG, Kim YW, Kim EH, Meng Z, Huang W, Hwang SJ, Kim SG. Farnesoid X receptor protects hepatocytes from injury by repressing miR-199a-3p, which increases levels of LKB1. Gastroenterology 2012; 142: 1206-1217.e7 [PMID: 22265968 DOI: 10.1053/j.gastro.2012.01.007]
71. Williamson RM, Price JF, Glancy S, Perry E, Nee LD, Hayes PC, Frier BM, Van Look LA, Johnston GI, Reynolds RM, Strachan MW. Prevalence of and risk factors for hepatic steatosis and nonalcoholic Fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 2011; 34: 1139-1144 [PMID: 21478462 DOI: 10.2337/dc10-2229]
72. Zhang Y, Lee FY, Barrera G, Lee H, Vales C, Gonzalez FJ, Willson TM, Edwards PA. Activation of the nuclear receptor FXR improves hyperglycemia and hyperlipidemia in diabetic mice. Proc Natl Acad Sci USA 2006; 103: 1006-1011 [PMID: 16410358 DOI: 10.1073/pnas.0506982103]
73. Zhang L, Wang YD, Chen WD, Wang X, Lou G, Liu N, Lin M, Forman BM, Huang W. Promotion of liver regeneration/repair by farnesoid X receptor in both liver and intestine in mice. Hepatology 2012; 56: 2336-2343 [PMID: 22711662 DOI: 10.1002/hep.25905]
74. Nomoto M, Miyata M, Yin S, Kurata Y, Shimada M, Yoshinari K, Gonzalez FJ, Suzuki K, Shibasaki S, Kurosawa T, Yamazoe Y. Bile acid-induced elevated oxidative stress in the absence of farnesoid X receptor. Biol Pharm Bull 2009; 32: 172-178 [PMID: 19182371]
75. Wu W, Zhu B, Peng X, Zhou M, Jia D, Gu J. Activation of farnesoid X receptor attenuates hepatic injury in a murine model of alcoholic liver disease. Biochem Biophys Res Commun 2014; 443: 68-73 [PMID: 24269813 DOI: 10.1016/j.bbrc.2013.11.057]
76. Mencarelli A, Renga B, Distrutti E, Fiorucci S. Antiatherosclerotic effect of farnesoid X receptor. Am J Physiol Heart Circ Physiol 2009; 296: H272-H281 [PMID: 19028791 DOI: 10.1152/ajpheart.01075.2008]
77. Xin X, Zhong M, Zhang S, Peng Y, Zhu W, Zhang Y. [Effects of farnesoid X receptor agonist on adiponectin and its receptors]. Nanfang Yike Daxue Xuebao 2014; 34: 109-112 [PMID: 24463129]
78. Gadaleta RM, van Erpecum KJ, Oldenburg B, Willemsen EC, Renooij W, Murzilli S, Klomp LW, Siersema PD, Schipper ME, Danese S, Penna G, Laverny G, Adorini L, Moschetta A, van Mil SW. Farnesoid X receptor activation inhibits inflammation and preserves the intestinal barrier in inflammatory bowel disease. Gut 2011; 60: 463-472 [PMID: 21242261 DOI: 10.1136/gut.2010.212159]
79. Fiorucci S, Rizzo G, Antonelli E, Renga B, Mencarelli A, Riccardi L, Orlandi S, Pruzanski M, Morelli A, Pellicciari R. A farnesoid x receptor-small heterodimer partner regulatory cascade modulates tissue metalloproteinase inhibitor-1 and matrix metalloprotease expression in hepatic stellate cells and promotes resolution of liver fibrosis. J Pharmacol Exp Ther 2005; 314: 584-595 [PMID: 15860571 DOI: 10.1124/jpet.105.084905]
80. Mudaliar S, Henry RR, Sanyal AJ, Morrow L, Marschall HU, Kipnes M, Adorini L, Sciacca CI, Clopton P, Castelloe E, Dillon P, Pruzanski M, Shapiro D. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013; 145: 574-582.e1 [PMID: 23727264 DOI: 10.1053/j.gastro.2013.05.042]
81. McMahan RH, Wang XX, Cheng LL, Krisko T, Smith M, El Kasmi K, Pruzanski M, Adorini L, Golden-Mason L, Levi M, Rosen HR. Bile acid receptor activation modulates hepatic monocyte activity and improves nonalcoholic fatty liver disease. J Biol Chem 2013; 288: 11761-11770 [PMID: 23460643 DOI: 10.1074/jbc.M112.446575]
82. Rizzo G, Passeri D, De Franco F, Ciaccioli G, Donadio L, Rizzo G, Orlandi S, Sadeghpour B, Wang XX, Jiang T, Levi M, Pruzanski M, Adorini L. Functional characterization of the semisynthetic bile acid derivative INT-767, a dual farnesoid X receptor and TGR5 agonist. Mol Pharmacol 2010; 78: 617-630 [PMID: 20631053 DOI: 10.1124/mol.110.064501]
83. Urizar NL, Liverman AB, Dodds DT, Silva FV, Ordentlich P, Yan Y, Gonzalez FJ, Heyman RA, Mangelsdorf DJ, Moore DD. A natural product that lowers cholesterol as an antagonist ligand for FXR. Science 2002; 296: 1703-1706 [PMID: 11988537 DOI: 10.1126/science.1072891]
84. Claudel T, Sturm E, Duez H, Torra IP, Sirvent A, Kosykh V, Fruchart JC, Dallongeville J, Hum DW, Kuipers F, Staels B. Bile acid-activated nuclear receptor FXR suppresses apolipoprotein A-I transcription via a negative FXR response element. J Clin Invest 2002; 109: 961-971 [PMID: 11927623 DOI: 10.1172/JCI14505]
85. Prawitt J, Abdelkarim M, Stroeve JH, Popescu I, Duez H, Velagapudi VR, Dumont J, Bouchaert E, van Dijk TH, Lucas A, Dorchies E, Daoudi M, Lestavel S, Gonzalez FJ, Oresic M, Cariou B, Kuipers F, Caron S, Staels B. Farnesoid X receptor deficiency improves glucose homeostasis in mouse models of obesity. Diabetes 2011; 60: 1861-1871 [PMID: 21593203 DOI: 10.2337/db11-0030]
86. Watanabe M, Horai Y, Houten SM, Morimoto K, Sugizaki T, Arita E, Mataki C, Sato H, Tanigawara Y, Schoonjans K, Itoh H, Auwerx J. Lowering bile acid pool size with a synthetic farnesoid X receptor (FXR) agonist induces obesity and diabetes through reduced energy expenditure. J Biol Chem 2011; 286: 26913-26920 [PMID: 21632533 DOI: 10.1074/jbc.M111.248203]